Early transition from medium-dose inhaled corticosteroids to biologic therapy in asthma is associated with significantly greater reductions in exacerbations and systemic corticosteroid use compared with escalation to high-dose ICS, suggesting a potential shift in treatment strategy for patients with severe disease or type 2 inflammation.
PHARMACOLOGYPulmonology < class="penci-entry-title entry-title grid-title penci_grid_title">Asthma exacerbations drop with medium-dose ICS to biologic switch